Invitae Catecholaminergic Polymorphic Ventricular Tachycardia Panel
Use
The Invitae Catecholaminergic Polymorphic Ventricular Tachycardia Panel is designed for individuals with a clinical diagnosis of catecholaminergic polymorphic ventricular tachycardia (CPVT). This test helps in diagnosing or confirming CPVT, clarifying risks, and informing management. It is also useful for asymptomatic family members with a known pathogenic variant to avoid symptom-triggering activities. The panel analyzes genes associated with CPVT and other inherited arrhythmia disorders with similar clinical features. CPVT is a genetically heterogeneous disorder characterized by arrhythmias that trigger during stress or exercise, potentially leading to serious cardiac events.
Special Instructions
For detailed clinical description, refer to the provided PDF. Turnaround time is 10-21 calendar days on average. It is New York approved and preferred specimen is whole blood in an EDTA tube. Saliva, buccal swab, and gDNA are acceptable alternatives. Contact client services for questions regarding test limitations and targeted regions.
Limitations
The assay may not detect all variants, especially those outside covered regions or complex variants such as structural rearrangements. Rare single-exon copy number events may remain unanalyzed. Explicit guarantee for promoter and non-coding regions is absent. Client services can be contacted for details on covered and excluded regions/variants.
New York Approved
Methodology
NGS (Targeted)
Biomarkers
Result Turnaround Time
10-21 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3mL
Minimum Volume
Not provided
Container
purple-top EDTA tube (K2EDTA or K3EDTA)